AgainChance was founded in 2006 by a group of researchers who are interested in adoptive T cell therapy. At present, we define ourselves as a material and service provider for improving therapeutic outcome of current cancer treatments and accelerating clinical application of T cell receptors (TCR). We are also actively involved in developing the second generation of TCR-redirected T cell therapies.

AgainChance is a provider of TCR genes with a rapidly growing product pipeline generated by our straight-forward strategy. TCR genes can be used in areas such as TCR-redirected T cell therapy and bi-specific T cell engager development. The therapeutic potential of these approaches in cancer treatment has been demonstrated in recent clinical trials. In addition, we have two undisclosed program reach clinical development stage.These programs combine immunotherapy with commercially available cancer drugs to improve therapeutic outcome of these drugs.

Our Company believes that widespread availability of TCR genes will facilitate rapid progress in T cell therapy and promote development of innovative targeted therapy. We are endeavoring to develop the second generation of TCR-redirected T cell therapy.